Recent Updates
Recently added Catalysts
ELAN Negative Sentiment

ELANCO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Elanco Animal Health Incorporated and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been filed against Elanco Animal Health Incorporated in the U.S. District Court for the District of Maryland. The suit alleges that the company made false and misleading statements regarding its products, specifically Zenrelia, which is claimed to be less safe than represented. Additionally, it is asserted that Elanco is unlikely to meet its previously promised timeline for the approval and launch of Zenrelia and Credelio Quattro. Investors are encouraged to participate in the lawsuit by applying to the court.
Price reaction · baseline $14.47 (2024-10-08 close) · hit after-hours · 4 other ELAN headline(s) in the window, move may be shared
day 0 close · peak
+0.8%

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Elanco, alleging misleading statements about the safety of Zenrelia.
  • The complaint claims that Elanco is unlikely to meet its own timeline for the U.S. approval and commercial launch of Zenrelia and Credelio Quattro.
  • Investors' expectations regarding the company's business and financial prospects were reportedly overstated.

Full Press Release Details

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Investors have until December 6, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Zenrelia was less safe than the Company had led investors to believe; (2) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro; (3) accordingly, the Company's business and/or financial prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Elanco shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is the class action lawsuit against Elanco about?

The lawsuit alleges Elanco made false statements about its business and products during a specific period.

What is the Class Period for the Elanco lawsuit?

The Class Period spans from November 7, 2023, to June 26, 2024.

When is the deadline to apply as lead plaintiff in the lawsuit?

Investors must apply to be lead plaintiff by December 6, 2024.

How can investors learn more about the Elanco claims?

Investors can contact Brandon Walker or Marion Passmore via email or phone for details.

What firm is handling the lawsuit against Elanco?

The lawsuit is being handled by Bragar Eagel & Squire, P.C.

Last updated: Oct 9, 2024